EU/3/06/361: Orphan designation for the treatment of cystic fibrosis


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2014 on request of the Sponsor.

On 11 April 2006, orphan designation (EU/3/06/361) was granted by the European Commission to Mukoviszidose e.V., Germany, for glutathione for the treatment of cystic fibrosis.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Intended use
Treatment of cystic fibrosis
Orphan designation status
EU designation number
Date of designation
Mukoviszidose e.V.
In den Dauen 6
53117 Bonn
Tel. +49 2289 87800
Fax +49 2289 878077

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating